1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Placebo Effect or Just Bad News? Omeros Down On OMS721 IgA Nephropathy Data

 
• By Sten Stovall

Investors and analysts hope Omeros Corp can explain – and soon - why its candidate drug for treating renal diseases performed only slightly better than placebo in tests on IgA nephropathy patients with high risk of progression, sending the biotech's shares sliding.

Kidney
Omeros Jarred Investors With Mixed Results In Its Phase II IgAN Study • Source: Shutterstock

A press release issued Oct. 1 by Omeros Corp. heralding 'positive' clinical trial results for its OMS721 drug in IgA nephropathy triggered a 44% drop in the company's share price when investors reached the fourth paragraph to learn it had fared only marginally better than placebo at 12 weeks.

The announcement from the Seattle-based biotech of additional Phase II results testing OMS721 in patients with IgA nephropathy (IgAN) was...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Kailera Eyes Global Obesity Market With Hengrui’s Phase III Dual Agonist

 
• By Joseph Haas

With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.

Sellas Targets Tambiciclib To Adverse-Risk Frontline AML Patients After Phase II Success

 
• By Alaric DeArment

The biotech announced positive Phase II data for the drug combined with AbbVie/Roche’s Venclexta and BMS’s Vidaza in relapsed/refractory acute myeloid leukemia.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 
• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By Kevin Grogan

Paying €90m upfront for rights to generalized pustular psoriasis drug.

More from R&D

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By Joseph Haas

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 
• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat

 
• By Andrew McConaghie

Rivals Mineralys could be first to file but AstraZeneca is banking on its cardiovascular market know-how to lead the emerging class.